SCHEDULE: Stonepine Capital Discloses 6% Stake in CalciMedica

Stonepine Capital Management, LLC and its affiliates have reported beneficial ownership of 6.0% of CalciMedica, Inc.'s common stock, including shares and warrants.

Summary

• Stonepine Capital Management, LLC, along with its affiliates Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico, have jointly filed a Schedule 13G.
• The filing indicates beneficial ownership of 2,149,522 shares of CalciMedica, Inc. common stock.
• This ownership represents 6.0% of the class of securities outstanding.
• The beneficial ownership includes 643,357 shares of common stock and warrants to acquire 1,506,165 shares, subject to a 9.99% beneficial ownership limitation.
• The percentage is calculated based on 34,141,460 shares outstanding as of August 5, 2026, as reported in CalciMedica's Form 10-Q for the quarter ending June 30, 2026.
• The reporting persons are filing jointly but not as members of a group, and each disclaims beneficial ownership beyond their pecuniary interest.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not dominant ownership stake by Stonepine Capital.

Positives

• Stonepine Capital, a significant investment firm, has taken a notable stake in CalciMedica, which could signal confidence in the company's future prospects.
• The disclosure of a 6.0% stake indicates substantial investment and potential for active engagement or influence.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• The ownership is reported as shared voting and dispositive power, with no sole voting or dispositive power, suggesting a passive investment rather than a controlling interest.

Risks

• The warrants to acquire shares are subject to a 9.99% beneficial ownership limitation, which could restrict future increases in ownership or require divestment if the limit is approached.
• As a Schedule 13G filing, it indicates passive investment, meaning Stonepine Capital is not seeking to control or influence the issuer's management, which may limit its ability to drive strategic changes.

Future Outlook

The filing itself is a disclosure of current ownership and does not contain forward-looking statements or guidance from CalciMedica, Inc. regarding its business operations or financial performance.

Management Comments

• Each reporting person also disclaims beneficial ownership of shares of Common Stock except to the extent of that person's pecuniary interest therein.
• The filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any shares of Common Stock covered by this Schedule 13G.

Industry Context

StockSavvy.ai notes that significant institutional ownership, as disclosed in Schedule 13G filings, often reflects investor confidence in a company's sector or specific growth potential. CalciMedica operates in the biotechnology sector, which is characterized by high R&D investment and potential for significant market disruption.

Stakeholder Impact

• Shareholders: The increased institutional interest may be viewed positively, potentially leading to greater scrutiny and support for the company's strategy.
• Management: The presence of a significant institutional investor may influence strategic decisions and corporate governance practices.
• Potential Investors: The disclosure may attract further investor attention to CalciMedica, Inc.

Next Steps

• Stonepine Capital will continue to hold its stake in CalciMedica, Inc.
• Further filings may be required if Stonepine Capital's ownership stake changes significantly or if their investment strategy shifts from passive to active.

Key Dates

Keywords

CalciMedica, Stonepine Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Management